Bibliographic record
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. New England Journal of Medicine 2023
§1Bibliographic record
§1.1Record
- Authors
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML
- Title
- Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
- Source
- New England Journal of Medicine
- Year
- 2023
- Volume, issue, pages
- 389(6):514–526
- Digital object identifier
- 10.1056/NEJMoa2301972
- PubMed identifier
- 37366315
- Record type
- Journal article
- Institute identifier
- CEI-BR-052
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Retatrutide | Compound monograph |
| Trial abstract: RETA-PH2-OBESITY | Trial abstract |
| Synthesis: Dual and triple incretin receptor agonists compared with single… | Evidence synthesis |
| Synthesis: Retatrutide in obesity and overweight in adults: effect on the anchor… | Evidence synthesis |
| Synthesis: Retatrutide in type 2 diabetes mellitus: effect on the anchor outcome | Evidence synthesis |
| Synthesis: Retatrutide in obesity and overweight in adults: tolerability and… | Evidence synthesis |
| Synthesis: Retatrutide in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Retatrutide in obesity and overweight in adults: durability of effect | Evidence synthesis |
| 8 citing documents. | |
§1.3Subject tags
retatrutide obesity TRIUMPH
Compound Evidence Institute · CEI-BR-052 · https://compoundevidence.com/bibliography/jastreboff2023/ · retrieved 30 July 2026